The influence of anti-tumor necrosis factor agents on hemoglobin levels of patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 21, Issue 7, 2015, Pages 1587-1593

  Koutroubakis, Ioannis E ^a   Ramos Rivers, Claudia ^a   Regueiro, Miguel ^a   Koutroumpakis, Efstratios ^a   Click, Benjamin ^a   Schwartz, Marc ^a   Swoger, Jason ^a   Baidoo, Leonard ^a   Hashash, Jana G ^a   Barrie, Arthur ^a   Dunn, Michael A ^a   Binion, David G ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

anemia; anti TNF; biologics; Crohn's disease; ulcerative colitis

Indexed keywords

ADALIMUMAB; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; HEMOGLOBIN; INFLIXIMAB; IRON; TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFLAMMATORY AGENT; IRON DERIVATIVE; TUMOR NECROSIS FACTOR;

ADULT; ANEMIA; ARTICLE; CROHN DISEASE; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE ASSOCIATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HARVEY BRADSHAW INDEX; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; IRON THERAPY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT RESPONSE; ULCERATIVE COLITIS; ULCERATIVE COLITIS ACTIVITY INDEX; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; DRUG EFFECTS; INFLAMMATORY BOWEL DISEASES; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADALIMUMAB; ADULT; ANEMIA; ANTI-INFLAMMATORY AGENTS; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; INFLAMMATORY BOWEL DISEASES; IRON COMPOUNDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84932085425     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000417     Document Type: Article

References (31)

1. Gasche C. Anemia in IBD: the overlooked villain. Inflamm Bowel Dis. 2000, 6:142-150.
2. Stein J, Dignass AU. Management of iron deficiency anemia in inflammatory bowel disease-A practical approach. Ann Gastroenterol. 2013;26: 104-113.
3. Oustamanolakis P, Koutroubakis IE, Kouroumalis EA. Diagnosing anemia in inflammatory bowel disease: beyond the established markers. J Crohns Colitis. 2011;5:381-391.
4. Wells CW, Lewis S, Barton JR, et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12:123-130.
5. Nissenson AR, Wade S, Goodnough T, et al. Economic burden of anemia in an insured population. J Manag Care Pharm. 2005;11:565-574.
6. Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211-222.
7. Billiet T, Rutgeerts P, Ferrante M, et al. Targeting TNF-A for the treatment of inflammatory bowel disease. Expert Opin Biol Ther. 2014;14: 75-101.
8. Papadaki HA, Kritikos HD, Valatas V, et al. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-Tumor necrosis factor-A antibody therapy. Blood. 2002;100:474-482.
9. Doyle MK, Rahman MU, Han C, et al. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-A pooled analysis from three large, multicenter, double-blind, randomized clinical trials. Semin Arthritis Rheum. 2008;39:123-131.
10. Furst DE, Kay J, Wasko MC, et al. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology (Oxford). 2013;52:1845-1855.
11. Ramos-Rivers C, Regueiro M, Vargas EJ, et al. Association between telephone activity and features of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:986-994.
12. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36.
13. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet. 1980;1:514.
14. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989;110:353-356.
15. Jowett SL, Seal CJ, Barton JR, et al. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am J Gastroenterol. 2001;96:2921-2928.
16. WHO, UNICEF, UNU. Iron Deficiency Anemia: Assessment, Prevention and Control. Report of a Joint WHO/UNICEF/UNU Consultation. Geneva, Switzerland: World Health Organization; 1998.
17. Reinisch W, Staun M, Tandon RK, et al. A randomized, open-label, noninferiority study of intravenous iron isomaltoside 1, 000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol. 2013;108:1877-1888.
18. Bergamaschi G, Di SA, Albertini R, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-Tumor necrosis factor-Alpha treatment. Haematologica. 2010;95:199-205.
19. Lonnkvist MH, Befrits R, Lundberg JO, et al. Infliximab in clinical routine: experience with Crohn's disease and biomarkers of inflammation over 5 years. Eur J Gastroenterol Hepatol. 2009;21:1168-1176.
20. Assa A, Hartman C, Weiss B, et al. Long-Term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease. J Crohns Colitis. 2013;7:369-376.
21. Filmann N, Rey J, Schneeweiss S, et al. Prevalence of anemia in inflammatory bowel diseases in European countries: a systematic review and individual patient data meta-Analysis. Inflamm Bowel Dis. 2014;20:936-945.
22. Wiskin AE, Fleming BJ, Wootton SA, et al. Anaemia and iron deficiency in children with inflammatory bowel disease. J Crohns Colitis. 2012;6:687-691.
23. Sjoberg D, Holmstrom T, Larsson M, et al. Anemia in a population-based IBD cohort (ICURE): still high prevalence after 1 year, especially among pediatric patients. Inflamm Bowel Dis. 2014;20:2266-2270.
24. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13:1545-1553.
25. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
26. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392-400.
27. Lee TW, Kolber MR, Fedorak RN, et al. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-Analysis. J Crohns Colitis. 2012, 6: 267-275.
28. Avni T, Bieber A, Steinmetz T, et al. Treatment of anemia in inflammatory bowel disease-systematic review and meta-Analysis. PLoS One. 2013;8:e75540.
29. Iqbal T, Stein J, Sharma N, et al. Clinical significance of C-reactive protein levels in predicting responsiveness to iron therapy in patients with inflammatory bowel disease and iron deficiency anemia. Dig Dis Sci. [published online ahead of print December 12, 2014]. doi: 10.1007/ s10620-014-3460-4.
30. Kulnigg S, Teischinger L, Dejaco C, et al. Rapid recurrence of IBD-Associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol. 2009;104: 1460-1467.
31. Evstatiev R, Alexeeva O, Bokemeyer B, et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:269-277.